Get the Stockscreener App
3.91
0.00%
0.10
Lantern Pharma Inc stock is traded at $3.91, with a volume of 4,435.
It is up +0.00% in the last 24 hours and up +25.71% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$4.01
Open:
$4.03
24h Volume:
4,435
Relative Volume:
0.03
Market Cap:
$42.82M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-2.1966
EPS:
-1.78
Net Cash Flow:
$-17.24M
1W Performance:
-0.50%
1M Performance:
+25.71%
6M Performance:
-11.87%
1Y Performance:
-13.02%
1-Day Range:
$3.97
$4.07
1-Week Range:
$3.835
$4.41
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.97 | 45.67M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.00 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.33 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.35 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.38 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
300.77 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors - BioSpace
Lantern Pharma Strengthens Board with AI and Oncology Expert Dr. Lee T. Schalop - citybuzz -
What makes Lantern Pharma Inc. stock price move sharplyDaily Trading Outlook With Proven Results - jammulinksnews.com
Lantern Pharma Appoints Dr. Lee Schalop To Board - citybiz
What institutional investors are buying Lantern Pharma Inc. stockInvest confidently with professional market insights - jammulinksnews.com
Lantern Pharma appoints biotech executive Lee Schalop to board By Investing.com - Investing.com Nigeria
Lantern Pharma appoints biotech executive Lee Schalop to board - Investing.com
What institutional flow reveals about Lantern Pharma Inc.Portfolio Booster Strategy with Trend Confidence - Newser
How Lantern Pharma Inc. stock performs during market volatility Weekly Signal Report with Trend Summary - Newser
What are the latest earnings results for Lantern Pharma Inc.Dynamic portfolio growth - jammulinksnews.com
What are analysts’ price targets for Lantern Pharma Inc. in the next 12 monthsBuild a diversified portfolio for risk mitigation - jammulinksnews.com
Is Lantern Pharma Inc. stock overvalued or undervaluedIdentify safe investments with exceptional yields - jammulinksnews.com
Is it the right time to buy Lantern Pharma Inc. stockExtraordinary market timing - jammulinksnews.com
Is Lantern Pharma Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Stock Selection with 300% Return - Newser
Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Investment Community - Newser
Intrinsic Value of Lantern Pharma Inc. Stock: Is It Undervalued or OvervaluedFree Discussion Group - Newser
How Resilient Is Lantern Pharma Inc. Stock During Economic DownturnsHigh Potential Safe Trades - Newser
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Published on: 2025-07-26 01:13:11 - PrintWeekIndia
What analysts say about Lantern Pharma Inc. stockRapid growth opportunities - PrintWeekIndia
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bellingham Herald
Is Lantern Pharma Inc. a good long term investmentFree Stock Market Real-Time Monitoring - Autocar Professional
Will Lantern Pharma Inc. stock benefit from interest rate changesExceptional gains - jammulinksnews.com
How Lantern Pharma Inc. stock performs during market volatilityBalanced Risk Reward Portfolio - Newser
Why Lantern Pharma Inc. stock is on top investor watchlistsOverwhelming financial success - jammulinksnews.com
Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional
What drives Lantern Pharma Inc. stock priceTremendous gains - Autocar Professional
Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL - Barchart.com
Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com Australia
Lantern Pharma reports complete response in aggressive lymphoma patient By Investing.com - Investing.com South Africa
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284 - The Globe and Mail
Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace
Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
1.73%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):